First Hawaiian Bank lifted its position in shares of DaVita Inc. (NYSE:DVA) by 7.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,563 shares of the company’s stock after purchasing an additional 533 shares during the quarter. First Hawaiian Bank’s holdings in DaVita were worth $888,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in DVA. Amundi Pioneer Asset Management Inc. boosted its position in shares of DaVita by 31.9% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 154,693 shares of the company’s stock worth $8,398,000 after purchasing an additional 37,375 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of DaVita by 25.0% during the second quarter. Captrust Financial Advisors now owns 2,058 shares of the company’s stock worth $166,000 after purchasing an additional 412 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of DaVita during the second quarter worth $136,000. Cigna Investments Inc. New bought a new position in shares of DaVita during the second quarter worth $223,000. Finally, Sei Investments Co. lifted its position in DaVita by 13.2% in the 2nd quarter. Sei Investments Co. now owns 46,137 shares of the company’s stock valued at $3,652,000 after acquiring an additional 5,396 shares in the last quarter. 95.27% of the stock is currently owned by institutional investors.
DVA has been the topic of several research reports. Zacks Investment Research cut shares of DaVita from a “buy” rating to a “hold” rating and set a $122.00 price objective on the stock. in a research report on Tuesday, January 5th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of DaVita from $105.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday. Truist boosted their price objective on shares of DaVita from $100.00 to $130.00 in a research report on Tuesday, January 5th. BidaskClub raised shares of DaVita from a “buy” rating to a “strong-buy” rating in a research report on Thursday, December 17th. Finally, Bank of America cut shares of DaVita from a “buy” rating to a “neutral” rating and set a $127.00 price objective on the stock. in a research report on Tuesday, January 5th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $117.33.
Shares of NYSE:DVA opened at $120.76 on Thursday. The company’s 50-day moving average price is $114.26 and its two-hundred day moving average price is $95.11. The company has a debt-to-equity ratio of 4.49, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a one year low of $62.20 and a one year high of $125.28. The stock has a market capitalization of $13.53 billion, a PE ratio of 18.10, a price-to-earnings-growth ratio of 0.84 and a beta of 1.30.
DaVita (NYSE:DVA) last issued its quarterly earnings results on Thursday, October 29th. The company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.44 by $0.36. DaVita had a net margin of 7.32% and a return on equity of 43.99%. The firm had revenue of $2.92 billion for the quarter, compared to analysts’ expectations of $2.94 billion. During the same period in the previous year, the firm posted $1.53 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. On average, analysts anticipate that DaVita Inc. will post 7.5 earnings per share for the current fiscal year.
DaVita Company Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Story: What is the NASDAQ?
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.